MACK Volume Alert - MACK 8.65 Merrimack Pharmaceuticals Inc

New Post Public Reply Private Reply Replies (0) Message Board

Nov 11, 2014 at 2:19 PM

MACK Volume Alert - MACK 8.65 Merrimack Pharmaceuticals Inc $MACK Hit a high of 8.65 Currently 11:14 Last price 8.65 -0.05 -0.57% With a day low of 8.10 and a current volume of 1,888,740.

MACK Merrimack Pharmaceuticals Inc Recent Headline News

Merrimack Pharma ups revenues 306% in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:09AM CST

MACK: 8.58 (-0.12)

Merrimack Pharmaceuticals' (MACK) CEO Bob Mulroy on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 9:29PM CST

MACK: 8.58 (-0.12)

Merrimack posts 3Q loss
Automated Insights - Mon Nov 10, 5:57PM CST
CAMBRIDGE, Mass. (AP) _ Merrimack Pharmaceuticals Inc. (MACK) on Monday reported a loss of $27.9 million, or 27 cents per share, in its third quarter.
MACK: 8.58 (-0.12)

Merrimack Pharmaceuticals Reports Third Quarter 2014 Financial Results
GlobeNewswire - Mon Nov 10, 3:11PM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer, today announced its third quarter 2014 financial results. Merrimack will host a live conference call and webcast today, Monday, November 10 at 4:30 p.m., Eastern Time, to provide an update on Merrimack's progress as well as a summary of these results.
MACK: 8.58 (-0.12)

Merrimack Pharmaceuticals misses by $0.15, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:09PM CST

MACK: 8.58 (-0.12)

What To Watch For: November 10-14
TipRanks - Seeking Alpha - Mon Nov 10, 10:36AM CST
Quarterly report releases are winding down as we reach mid-November. Stay ahead of Wall Street with this week’s top stories: Monday, November 10 Sotheby’s (NYSE: BID ): a worldwide broker of fine art and real estate ...
BID: 41.53 (+0.08), DHI: 24.01 (+0.58), MGNX: 20.79 (+0.55), KSS: 56.17 (-0.40), HK: 2.99 (-0.26), SEAS: 18.56 (+0.11), DDD: 34.68 (-1.54), SBH: 28.67 (-0.01), WMT: 78.91 (-0.53), M: 58.66 (-0.60), HP: 85.92 (-0.48), NTAP: 42.33 (+0.18), ENR: 124.84 (-0.24), MACK: 8.58 (-0.12), W: 24.28 (-3.82), FOSL: 103.32 (+0.10), AMAT: 22.51 (-0.12), JCP: 7.14 (-0.08), JWN: 70.65 (-1.74), PE: 16.67 (+0.21), DF: 16.26 (-0.14), VIAB: 69.37 (-0.72), CSCO: 25.15 (unch), ATW: 35.27 (-2.49)

Will Inovio (INO) Disappoint Expectations for Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 3:35PM CST
Inovio (INO), which is scheduled to report third-quarter results on Nov 10, had delivered a negative earnings surprise of 11.76% in the last quarter.
MACK: 8.58 (-0.12), MNK: 92.85 (-0.38), INO: 11.34 (+0.10)

Can Merrimack (MACK) Keep the Earnings Streak Alive in Q3? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 3:30PM CST
Merrimack Pharmaceuticals, Inc. (MACK) has a Zacks Rank #2 and an Earnings ESP of +437.50%.
MACK: 8.58 (-0.12), MNK: 92.85 (-0.38), BAX: 70.57 (-0.06), LLY: 67.98 (-0.37)

Will Intercept Pharmaceuticals' (ICPT) Q3 Loss Narrow? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 3:02PM CST
Intercept Pharmaceuticals, Inc (ICPT) is slated to report its third-quarter 2014 results on Nov 7.
MACK: 8.58 (-0.12), MNK: 92.85 (-0.38), DNDN: 0.16 (-0.02), ICPT: 172.78 (-3.57)

Merrimack Pharmaceuticals Announces Initiation of Phase 1 Clinical Study of MM-398 for Brain Cancer
GlobeNewswire - Thu Nov 06, 7:42AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the first patient has been enrolled in a Phase 1 clinical study of MM-398 (nanoliposomal irinotecan injection) in a highly concentrated formulation in patients with recurrent high grade glioma, a type of aggressive brain tumor with poor prognosis. The study is being sponsored and conducted by Dr. Nicholas Butowski, M.D., Associate Professor of Neurological Surgery and Principal Investigator of the study at the University of California, San Francisco, and is supported by research grants from the National Institutes of Health and Merrimack.
MACK: 8.58 (-0.12), BAX: 70.57 (-0.06)

What's in Store for TrovaGene (TROV) This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 2:40PM CST
TrovaGene Inc. (TROV) is set to report third-quarter 2014 results on Nov 6.
MACK: 8.58 (-0.12), TROV: 4.82 (unch), PTCT: 40.86 (-0.81), HSIC: 129.23 (-0.39)

Merrimack cancer candidate tagged an Orphan Drug
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 10:26AM CST

MACK: 8.58 (-0.12)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 8:16AM CST

TTPH: 22.65 (-1.23), AWAY: 30.79 (+1.13), PHMD: 2.70 (-0.04), ROYT: 9.85 (-0.04), VG: 3.72 (+0.12), MEMP: 16.68 (-0.19), MACK: 8.58 (-0.12), ATVI: 20.57 (-0.35), NUS: 40.10 (-1.54), SSYS: 101.40 (-3.49), EOG: 98.52 (+0.02), CLNY: 24.64 (+0.29), CRTO: 36.94 (+0.49), IBIO: 1.17 (-0.06), NICE: 46.12 (+0.64), VPCO: 1.62 (-0.13), ZU: 29.43 (+0.60), EXEL: 1.79 (unch), ANV: 1.15 (+0.05), FEYE: 32.59 (+0.20), JIVE: 6.61 (+0.17), TRIP: 69.30 (-3.59), WLT: 3.02 (-0.14), YOD: 2.64 (-0.03), CHUY: 22.40 (-0.86), ANR: 2.62 (-0.02), NG: 2.92 (+0.23), AEZS: 0.60 (-0.02), ARIA: 6.32 (+0.03), CTSH: 52.94 (-0.71)

FDA Grants Orphan Drug Designation to Merrimack Pharmaceuticals' MM-141 for the Treatment of Pancreatic Cancer
GlobeNewswire - Wed Nov 05, 8:09AM CST
Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to their investigational drug candidate MM-141 for the treatment of pancreatic cancer. MM-141 is a tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes containing IGF-1R and ErbB3 (HER3). The IGF-1R and HER3 complexes both activate a major cellular signaling pathway that allows tumor cells to grow and develop resistance to therapies.
MACK: 8.58 (-0.12)

Is a Surprise Coming for Merrimack Pharmaceuticals (MACK) This Earnings Season? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:36AM CST
Merrimack Pharmaceuticals has a favorable Zacks Rank and an ESP in positive territory, thus investors might want to consider this stock ahead of earnings.
MACK: 8.58 (-0.12)

Will Humana (HUM) Miss on Earnings Estimates this Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 2:50PM CST
Humana Inc. (HUM) is set to report third-quarter 2014 earnings results on Nov 7, 2014.
MACK: 8.58 (-0.12), MDVN: 107.80 (-1.15), ALNY: 99.59 (+0.41), HUM: 135.20 (+2.74)

Merrimack Pharma reports November 10
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 9:53AM CST

MACK: 8.58 (-0.12)

Prosensa Holding N.V. (RNA) Jumps: Stock Moves Up 9.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 8:39AM CST
Prosensa Holding N.V. (RNA) was a big mover last session, as its shares rose nearly 10% on the day.
MDVN: 107.80 (-1.15), MACK: 8.58 (-0.12), RNA: 12.01 (+0.01), ILMN: 187.20 (-1.07)

Alder Biopharmaceuticals (ALDR) Jumps: Stock Rises 6.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 7:51AM CST
Alder Biopharmaceuticals Inc. (ALDR) was a big mover last session, as its shares rose nearly 7% on the day.
MDVN: 107.80 (-1.15), MACK: 8.58 (-0.12), ALDR: 16.94 (+0.03), ILMN: 187.20 (-1.07)

Oncolytics Biotech (ONCY) Looks Strong: Stock Up 21.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 7:44AM CST
Oncolytics Biotech Inc. (ONCY) was a big mover last session, as the company saw its shares surge nearly 22% on the day
MACK: 8.58 (-0.12), MDVN: 107.80 (-1.15), ONCY: 0.82 (-0.02), ILMN: 187.20 (-1.07)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vertiv's SmartIT: The New AI Infrastructure Game-Changer

Taking AI Infrastructure Up a Notch Vertiv Holdings Co. (NYSE: VRT) is charging ahead with a solution that's bound to rattle the cages of status quo infrastructure deployments. Say hello to Vertiv™ SmartIT, a finely-tuned piece of kit that's pre-engineered to ease up the often painful process of high-density AI deployments across various environments—from homey...

Custom Concrete: Crafting the Perfect Poolside Paradise

Concrete: The Unsung Hero of Your Pool's Success You know, everyone always raves about that sparkling pool, but let's be real—it's the concrete holding the whole gig together. James White from White's Pools in Loganville, GA, drops some knowledge in a recent HelloNation piece about the unsung hero of backyard oases: custom concrete. Yeah, it's not sexy, but when you're...

Better Home & Finance Faces 28.5% Stock Plunge, Lawsuit

The Sudden Dive in Better Home's Stock Imagine cruising down the highway with the wind in your hair and suddenly slamming into a pothole. That's the kind of jarring experience Better Home & Finance Holding Company (NASDAQ: BETR) investors felt when the stock took a nosedive, diving a hefty 28.5%. Back on May 7, 2026, the company released financial figures that flipped the...

Cumberland Pharmaceuticals Eyes NDA for Ifetroban in DMD

Rolling the Dice with Ifetroban There's a buzz in the air around Cumberland Pharmaceuticals as they gear up to tackle one of medicine's stubborn giants, Duchenne muscular dystrophy (DMD). They plan to file a New Drug Application (NDA) with the FDA for ifetroban, aiming to treat the cardiomyopathy plaguing many DMD sufferers. Folks who’ve watched Cumberland (NASDAQ:CPIX)...

Federal Law Shifts Landscape for Manufactured Housing

Federal Act Aims to Boost Manufactured Homes Price tags on homes need a reality check, and for a long time, manufactured housing has been in the corner looking for a chance to throw its hat in the ring. Enter the 21st Century ROAD to Housing Act, aiming to finally unlock the potential sitting in our backyards when it comes to these factory-built options. We're talking...

Gildan Activewear Faces Major Class Action Lawsuit

Investors Turn Against Gildan Activewear Ever see a freight train barreling down the track? That's what it feels like when a class action lawsuit rears its head against a behemoth like Gildan Activewear Inc. (NYSE: GIL). After years of allegedly pulling the wool over investors' eyes, those same investors are now being called to muster—their chance to lead a charge of...

Temu Partners with Recyclia to Drive EPR Compliance Boost

Temu and Recyclia: Building a Sustainable Marketplace Get this: Temu, the e-commerce giant you've heard trumpeting about affordable goods like some digital bazaar, is diving deeper into sustainability waters with a partner that knows a thing or two about waste. This time, they've linked up with Recyclia over in Spain. The duo's focus? Helping marketplace sellers meet the...

3TREES Debuts Green Coatings to East African Market

3TREES Rocks East Africa's Construction Scene Nairobi's got a spark this week, and it's radiating straight from 3TREES' corner at the Big 5 Construct Kenya. With the Sarit Expo Centre buzzing from October 21, 2026, this Chinese company didn't just show up—they made one hell of an entrance. Presenting eco-friendly coating solutions, they pushed the 'Create Healthy Life'...

Superteam Wheels Rides Into Spain with RACEIT Deal

Rolling Out the Red Carpet for Spanish Cyclists Think of it as the pedal-powered bridge from wherever Superteam Wheels calls home to the sunny streets of Spain. If you're in the cycling game, this new partnership between Superteam Wheels and COMERTECH RACEIT, S.L., better known as RACEIT, is drawing a line in the sand—or perhaps on the asphalt—across Europe. Starting...

Sintilimab Poised for New Milestone in Melanoma Fight

An Opening Shot: NMPA's Decision Window Well, here's the latest chapter in the saga of battling advanced melanoma with some real gritty numbers behind it. Innovent Biologics has thrown its hat back in the ring with news that the China National Medical Products Administration (NMPA) has embraced a new indication application for their drug sintilimab. They're teaming it up...